M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 25.68 CNY 0.71% Market Closed
Market Cap: 11.1B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Mayinglong Pharmaceutical Group Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayinglong Pharmaceutical Group Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
PP&E Gross
ÂĄ686.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
PP&E Gross
ÂĄ3.3B
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
PP&E Gross
ÂĄ854.4m
CAGR 3-Years
12%
CAGR 5-Years
26%
CAGR 10-Years
11%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
PP&E Gross
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
PP&E Gross
ÂĄ3.6B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
PP&E Gross
ÂĄ534.8m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.1B CNY
Industry
Pharmaceuticals

Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei and currently employs 3,208 full-time employees. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.

Intrinsic Value
30.62 CNY
Undervaluation 16%
Intrinsic Value
Price
M

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's PP&E Gross?
PP&E Gross
686.1m CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's PP&E Gross amounts to 686.1m CNY.

Back to Top